![shutterstock_1384219187_picturedesignswiss](https://cdn.lifesciencesipreview.com/convert/files/2023/08/5d55e0b0-4112-11ee-8179-0f0ce8051b03-shutterstock_1384219187_picturedesignswiss.jpg/r%5Bwidth%5D=320/5d55e0b0-4112-11ee-8179-0f0ce8051b03-shutterstock_1384219187_picturedesignswiss.webp)
PictureDesignSwiss / Shutterstock.com
23 June 2020Americas
Mylan scores multiple sclerosis patent win over Biogen
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Biotechnology
21 September 2020 In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Big Pharma
25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.
Americas
20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Editor's picks
Editor's picks
Biotechnology
21 September 2020 In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Big Pharma
25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.
Americas
20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Biotechnology
21 September 2020 In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Big Pharma
25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.
Americas
20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.